Nature Reviews Immunology - T cell fate is determined by the unequal degradation of a key transcriptional regulator. Skip to main content. Thank you for visiting nature.com.

'Goldilocks' binding strength determines anti-cancer T-cell efficacy and fate. ScienceDaily. Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 / 05 / 240530132720.htm.

Jensen, D. C. et al. Thymic selection determines γδ T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon γ. Immunity 26 June 2008 (doi:10. ...

CD8+ T cell fate is governed by TCR signals, co-stimulatory molecules, and cytokines, with transcription factor (TF) networks dictating effector vs. memory differentiation (Figure 4).

Fate Therapeutics, Inc. shows promise in the cell therapy market with the successful CAR T-cell project, but high cash burn rate may pose a risk. Learn more on FATE stock here.

Scientists have identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model. Scientists at St. Jude Children's Research Hospital ...

The first candidate is what I previously viewed as the flagship project for FATE. FT819 is am iPSC-derived CAR T-cell therapy designed to target CD19 on B cells.

T helper (TH) cells are essential immune cells that help other immune cells function effectively. When activated in response ...

During the immune response, many immune cells undergo maturation into cells with enhanced functions that enable them to respond to particular types of pathogens in specific ways. This is called ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress ...